Patients with untreated or active hepatitis B or C infection
Are untreated.
Patients must have previously untreated disease (except for one week or less of corticosteroids)
Untreated active HBV
Patients who are on active surveillance for untreated localized disease may not participate in this study
Symptomatic untreated strictures
Untreated cutaneous T-Cell non-Hodgkin lymphoma (CTCL) (with the exception of untreated tumor stage Mycosis fungoides)
Previously untreated
Presence of active untreated infection
Previously untreated patients who decline standard therapy for their cancer are allowed to enroll
Known untreated or uncontrolled acute infection, including urinary tract infection, within  days of study entry
Untreated active infection
No known prior history or current evidence of untreated local gum or oral infection
Untreated active infection
Uncontrolled active, untreated, or progressive infection
Untreated active major depression
Uncontrolled active, untreated, or progressive infection
Untreated active infection
Untreated active infection
Symptomatic cognitive or emotive disorder such as untreated schizophrenia, severe untreated depression, anxiety; this is determined by clinical assessment
Presence of any untreated systemic infection
Patients with untreated or uncontrolled neuropsychiatric illness
Evidence of untreated infection
Previously untreated patients with locoregional-only disease are not eligible
Patient with confirmed delq mutation may be included if untreated
Presence of active untreated infection
Patient has untreated severe hypothyroidism
Untreated, uncontrolled Sleep apnea
Other untreated coexisting HIV related malignancies.
Patients must be untreated with radiation above the clavicles
Active untreated infection
Patients with known untreated hepatitis C
Untreated psychiatric conditions preventing informed consent
Untreated systemic infection
Untreated or uncontrolled nd malignancy
Hepatitis B or C infection (HBV), or untreated systemic infection
Untreated first hematologic relapse is defined as:
Known untreated or unstable CNS metastatic disease.
For participants enrolled in the expansion phase: lymphoma classified as either previously untreated Grade , , or a FL that requires treatment or previously untreated advanced DLBCL
Untreated hepatitis B infection
Any serious ongoing condition, such as an untreated infection or organ dysfunction
The presence of co-existing medical conditions that would limit compliance with study medications, including, but not limited to active infection, active or untreated cardiac or pulmonary disease, or malignancy
Previously untreated participants are eligible if their tumor(s) are measurable
Patients must be previously untreated
UNTREATED PRIMARY:
Untreated N mediastinal nodal disease
Active untreated infection
Untreated urinary-tract infection
An untreated tumor growth rate of < .% during the Screening period may exclude some patients.
Active untreated infection
Has untreated hypo- or hyperthyroidism;
Grade >= uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia
Untreated bladder infection
Untreated active, or inappropriately/inadequately treated breast malignancy, without surgical treatment
Male patients with a history of untreated hypogonadism
Patients with untreated clinically relevant hypothyroidism
Severe or untreated psychiatric disease
Have a diagnosis of untreated hypo- or hyper- thyroidism
Patients with any of the following conditions: untreated gastrointestinal reflux disease; untreated diabetes mellitus; active thrush; active oral infection; active mucositis
Patients with any of the following conditions: untreated gastrointestinal reflux disease; untreated diabetes mellitus; active thrush; active oral infection; active mucositis
Untreated active infection
Untreated; OR
 or more decayed, untreated dental sites (cavities)
Previously untreated sarcomas
Previously untreated subjects must have a lesion on an imaging study
Untreated/unstabilized pathologic long bone fractures
